GSK exec joins Novelion Therapeutics as EVP/head of R&D
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Murray Stewart will become Novelion Therapeutics Inc.'s executive vice president and head of research and development Nov. 27.
Stewart is joining Novelion Therapeutics from GlaxoSmithKline plc, where he serves as the chief medical officer.
